Does immunohistochemical staining predict mobilization success in multiple myeloma patients?
Özet
Background: So many risk factors for mobilization failure have been described so far. We aimed to identify the
risk factors and search the possible effects of bone marrow fibrosis (BMF), CD56, c-myc, and cyclinD1 expression
on mobilization.
Methods: We evaluated 189 patients with MM who were admitted for stem cell mobilization before autologous
stem cell transplantation (ASCT) between 2015 and June 2021. Clinical, laboratory, treatment features, and
survival outcomes were compared in patients who were successfully mobilized and who were not.
Results: Mobilization failure rate was 11.1 % (21) in our study group. Male gender, mobilization with only G-CSF,
history of previous ASCT, lenalidomide exposure, and 2 lines of chemotherapy before stem cell mobilization were
observed more commonly in mobilization failure group. There is no relationship between mobilization failure
and BMF, CD56, c-myc, and cyclin D1 expression status in patients who received either only G-CSF or G-CSF+
chemotherapy for mobilization. Overall survival (OS) was not different in groups of patients who were suc
cessfully mobilized and who were not. Neutrophil engraftment was faster in patients who were transfused > 5 ×
106
/kg stem cells (p = 0.015). ECOG performance status (p = 0.004), c-myc expression (p = 0.005), lenalido
mide therapy before mobilization (p = 0.032), and mobilization with G-CSF+chemotherapy was found to be
predictive factors for OS.
Conclusion: Even though we could not find any predictive value of CD56, c-myc, and cyclin D1 expression on
mobilization, c-myc was found to be associated with low OS. Further studies with large and homogenous study
population would be more informative.
